BR112021019593A2 - Composição, método de entrega de um carboidrato, método para tratar um distúrbio congênito de glicosilação (cdg), kit - Google Patents
Composição, método de entrega de um carboidrato, método para tratar um distúrbio congênito de glicosilação (cdg), kitInfo
- Publication number
- BR112021019593A2 BR112021019593A2 BR112021019593A BR112021019593A BR112021019593A2 BR 112021019593 A2 BR112021019593 A2 BR 112021019593A2 BR 112021019593 A BR112021019593 A BR 112021019593A BR 112021019593 A BR112021019593 A BR 112021019593A BR 112021019593 A2 BR112021019593 A2 BR 112021019593A2
- Authority
- BR
- Brazil
- Prior art keywords
- carbohydrate
- cdg
- glycosylation
- kit
- treating
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7032—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyldiacylglycerides, lactobionic acid, gangliosides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
- A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Dispersion Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Organic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biophysics (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Dermatology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962826874P | 2019-03-29 | 2019-03-29 | |
| PCT/US2020/025246 WO2020205530A1 (en) | 2019-03-29 | 2020-03-27 | Liposomal formulations, and methods of using and preparing thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112021019593A2 true BR112021019593A2 (pt) | 2021-12-14 |
Family
ID=72666933
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112021019593A BR112021019593A2 (pt) | 2019-03-29 | 2020-03-27 | Composição, método de entrega de um carboidrato, método para tratar um distúrbio congênito de glicosilação (cdg), kit |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US20220184107A1 (https=) |
| EP (1) | EP3946365A4 (https=) |
| JP (1) | JP7583741B2 (https=) |
| KR (1) | KR20210143906A (https=) |
| CN (1) | CN113873998A (https=) |
| AR (1) | AR119705A1 (https=) |
| AU (1) | AU2020252005B2 (https=) |
| BR (1) | BR112021019593A2 (https=) |
| CA (1) | CA3134828A1 (https=) |
| CL (1) | CL2021002512A1 (https=) |
| CO (1) | CO2021014274A2 (https=) |
| EA (1) | EA202192663A1 (https=) |
| IL (1) | IL286713B2 (https=) |
| MX (1) | MX2021011876A (https=) |
| PE (1) | PE20212366A1 (https=) |
| PH (1) | PH12021552428A1 (https=) |
| SG (1) | SG11202110623PA (https=) |
| TW (1) | TWI906214B (https=) |
| WO (1) | WO2020205530A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023205628A1 (en) * | 2022-04-18 | 2023-10-26 | City Of Hope | Lipid nanoparticles, nucleic acids, and methods of use |
| TW202543582A (zh) * | 2024-02-29 | 2025-11-16 | 美商葛里柯麥公司 | 脂質體調配物及其使用及製備方法 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1156783B1 (en) * | 1999-03-02 | 2007-10-24 | Transave, Inc. | Encapsulation of bioactive complexes in liposomes |
| US7060291B1 (en) * | 1999-11-24 | 2006-06-13 | Transave, Inc. | Modular targeted liposomal delivery system |
| WO2002076428A1 (en) * | 2001-03-26 | 2002-10-03 | Alza Corporation | Liposome composition for improved intracellular delivery of a therapeutic agent |
| AU2003205048B2 (en) * | 2002-01-09 | 2009-02-26 | Transave, Inc. | Efficient liposomal encapsulation |
| WO2003059322A1 (en) * | 2002-01-09 | 2003-07-24 | Elan Pharmaceuticals, Inc. | Efficient nucleic acid encapsulation into medium sized liposomes |
| WO2010130896A2 (fr) * | 2009-05-14 | 2010-11-18 | Sanofi Pasteur | Procédé pour adjuver le lipopolysaccharide (lps) des bactéries à gram-négatif |
| MX366055B (es) | 2011-08-31 | 2019-06-26 | Novartis Ag | Liposomas pegilados para admistracion de acido ribonucleico (arn) que codifica para inmunogeno. |
| CA2890725A1 (en) | 2012-11-05 | 2014-05-08 | Pronai Therapeutics, Inc. | Methods of using biomarkers for the treatment of cancer by modulation of bcl2|expression |
| DK3954360T3 (da) * | 2013-09-16 | 2025-05-12 | Glycomine Inc | Farmaceutisk præparat af kulhydrater til terapeutisk anvendelse |
| JP2017537650A (ja) | 2014-10-09 | 2017-12-21 | ライポテック・ピーティーワイ・リミテッド | キメラタンパク質 |
| US20170165374A1 (en) * | 2015-11-18 | 2017-06-15 | Insmed, Inc. | Compositions and methods for treating bacterial infections |
-
2020
- 2020-03-27 AU AU2020252005A patent/AU2020252005B2/en active Active
- 2020-03-27 EA EA202192663A patent/EA202192663A1/ru unknown
- 2020-03-27 BR BR112021019593A patent/BR112021019593A2/pt unknown
- 2020-03-27 WO PCT/US2020/025246 patent/WO2020205530A1/en not_active Ceased
- 2020-03-27 CA CA3134828A patent/CA3134828A1/en active Pending
- 2020-03-27 SG SG11202110623PA patent/SG11202110623PA/en unknown
- 2020-03-27 AR ARP200100841A patent/AR119705A1/es unknown
- 2020-03-27 IL IL286713A patent/IL286713B2/en unknown
- 2020-03-27 JP JP2021560323A patent/JP7583741B2/ja active Active
- 2020-03-27 TW TW109110461A patent/TWI906214B/zh active
- 2020-03-27 PH PH1/2021/552428A patent/PH12021552428A1/en unknown
- 2020-03-27 US US17/593,755 patent/US20220184107A1/en active Pending
- 2020-03-27 EP EP20782039.0A patent/EP3946365A4/en active Pending
- 2020-03-27 CN CN202080038191.4A patent/CN113873998A/zh active Pending
- 2020-03-27 MX MX2021011876A patent/MX2021011876A/es unknown
- 2020-03-27 KR KR1020217035257A patent/KR20210143906A/ko active Pending
- 2020-03-27 PE PE2021001645A patent/PE20212366A1/es unknown
-
2021
- 2021-09-28 CL CL2021002512A patent/CL2021002512A1/es unknown
- 2021-10-26 CO CONC2021/0014274A patent/CO2021014274A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3946365A4 (en) | 2023-04-19 |
| SG11202110623PA (en) | 2021-10-28 |
| CN113873998A (zh) | 2021-12-31 |
| AU2020252005A1 (en) | 2021-11-04 |
| JP2022527638A (ja) | 2022-06-02 |
| MX2021011876A (es) | 2022-01-04 |
| AR119705A1 (es) | 2022-01-05 |
| CL2021002512A1 (es) | 2023-01-06 |
| KR20210143906A (ko) | 2021-11-29 |
| AU2020252005B2 (en) | 2025-11-27 |
| CA3134828A1 (en) | 2020-10-08 |
| EP3946365A1 (en) | 2022-02-09 |
| JP7583741B2 (ja) | 2024-11-14 |
| EA202192663A1 (ru) | 2022-03-01 |
| TWI906214B (zh) | 2025-12-01 |
| US20220184107A1 (en) | 2022-06-16 |
| WO2020205530A1 (en) | 2020-10-08 |
| IL286713A (en) | 2021-10-31 |
| IL286713B1 (en) | 2025-03-01 |
| PE20212366A1 (es) | 2021-12-21 |
| IL286713B2 (en) | 2025-07-01 |
| TW202102231A (zh) | 2021-01-16 |
| CO2021014274A2 (es) | 2022-01-17 |
| PH12021552428A1 (en) | 2022-07-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Argilés et al. | Muscle wasting in cancer: the role of mitochondria | |
| BR112020026125A8 (pt) | Compostos oligonucleotídeos superiores ou 5'-cap- trinucleotídeo e seus usos na estabilização de rna, expressão de proteínas e em terapia | |
| MX2020007853A (es) | Composiciones farmaceuticas para el tratamiento de fibrosis quistica. | |
| BR112022004248A2 (pt) | Composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, método para inibir a atividade de prmt5 em uma célula, e, método para o tratamento de câncer | |
| BR112019000528A2 (pt) | distribuição mediada por ve de conjugados de proteína de ligação-molécula pequena | |
| BR112021015815A2 (pt) | Métodos para tratar colestase | |
| MX2026002469A (es) | Nuevas moleculas de acido nucleico artificiales | |
| MX2022016415A (es) | Inhibidores de glicolato oxidasa para el tratamiento de enfermedades. | |
| BR112022008214A2 (pt) | Composições e métodos para tratar perda auditiva neurossensorial usando sistemas de vetor duplo de otoferlina | |
| BR112021019256A2 (pt) | Moduladores de receptor x4 de proteína g relacionado a mas e produtos e métodos relacionados | |
| BR112018014288A2 (pt) | métodos e composições para o tratamento de doença neurológica | |
| BR112022013042A2 (pt) | Composto da fórmula b, formulação farmacêutica, composição farmacêutica, método para tratar ou prevenir hiperglicemia, diabetes e/ou obesidade | |
| BR112017013599A2 (pt) | composição farmacêutica, e, método para prevenir, tratar ou melhorar um ou mais sintomas de um tumor maligno associado à mutação de kras. | |
| BR112012014066A2 (pt) | preparações de combinações com exossomos e corticosteróide | |
| BR112021019593A2 (pt) | Composição, método de entrega de um carboidrato, método para tratar um distúrbio congênito de glicosilação (cdg), kit | |
| BR112021021676A2 (pt) | Uso de preparação de exossomo de células-tronco mesenquimais para a preparação de composição para o tratamento da doença periodontal | |
| BR112021020011A2 (pt) | Preparação e armazenamento de formulações de rna lipossômico adequadas para terapia | |
| MX2021015874A (es) | Inhibidores de glicolato oxidasa para el tratamiento de enfermedades. | |
| EP4332576A3 (en) | Synergistic enhancement of the delivery of nucleic acids via blended formulations | |
| BR112013006355A2 (pt) | profármacos de éster de [3-(1-(1h-imidazol-4-il)etil-2-metilfenil] metanol para tratar doenças retinais | |
| NZ758331A (en) | B cells for in vivo delivery of therapeutic agents and dosages thereof | |
| MX2021011958A (es) | Terapias genicas para trastornos lisosomales. | |
| BR112015023009A2 (pt) | Moduladores de ship1 e métodos relacionados ao mesmo | |
| BR112015022469A2 (pt) | peptídeo ou análogo seu, composição, método para melhorar um sinal ou sintoma, método para estimular o crescimento de células, método para produção de uma população de células, método para aumentar o número de células, método para redução em um indivíduo diabético da tolerância à glicose debilitada, método para a promoção de neuroproteção ou regeneração nervosa, método para a promoção da regeneração, método para a inibição de inflamação, composição farmacêutica e uso de um peptídeo ou análogo seu | |
| BR112016024440A2 (pt) | composições para tratamento bucal |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] |